Navigation Links
Wayne State researcher developing treatments for Parkinson's with aid of $2.15 million NIH grant

DETROIT A Wayne State University professor is leading research efforts to develop new treatment options to slow the progression of Parkinson's disease, a neurodegenerative disorder that affects nearly six million people around the world, with 50,000 to 60,000 new cases diagnosed in the United States alone each year. Symptoms of Parkinson's disease may include tremor, slowed motion, rigid muscles, difficulty initiating movement, speech changes, postural instability and more.

Currently no ideal therapies are available for slowing the degeneration process while relieving symptomatic abnormalities associated with Parkinson's disease. Aloke Dutta, Ph.D., professor of pharmaceutical sciences in WSU's Eugene Applebaum College of Pharmacy and Health Sciences, is hoping to change that with a recently awarded $2.15 million research grant, Novel Neuroprotective Treatment for Parkinson's Disease, from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health. Dutta and his team aim to develop multifunctional therapeutic agents that will be useful not only in symptomatic treatment of Parkinson's disease, but also as disease-modifying agents promoting survival of the dopamine neurons that would otherwise gradually degenerate in Parkinson's disease.

According to Dutta, the etiology of Parkinson's disease is poorly understood, but both oxidative stress and mitochondrial dysfunction resulting from loss of glutathione coupled with increased concentration of free iron have been strongly implicated in dopamine cell death. In this regard, alpha-synuclein, a protein involved in fibrillization, has also been connected to Parkinson's disease.

"It is increasingly evident that for a complex disease such as Parkinson's, a drug targeting only one specific site will only partially address the therapeutic needs of the disease," said Dutta. "A growing body of literature suggests that suitable multifunctional drugs might be more effective to act as disease modifying agents. The overall goal of our research is to develop multifunctional therapeutic agents which will be useful not only in symptomatic treatment, but also as disease-modifying agents promoting survival of dopamine neurons."

"Our initial studies indicate facile blood-brain barrier crossing ability of such compounds developed by us," said Dutta. "The lead drugs we are developing have shown positive results in animal models of Parkinson's disease, and one of our lead molecules is exhibiting a neuroprotection property that may be critical to slowing the further progression of Parkinson's disease while being symptomatically beneficial in alleviating motor dysfunction."

The team aims to begin pre-clinical validation of these treatment agents soon. If results are positive, Dutta's study would shift the current research paradigm of Parkinson's disease by expanding treatment beyond that of acute motor defects stemming from dopamine deficiency.


Contact: Julie O'Connor
Wayne State University - Office of the Vice President for Research

Related medicine news :

1. Wayne State University study aims to improve diabetes management in high-risk youth
2. Wayne State University partners with Toyota on safety research
3. Wayne State University researcher to study spinal muscular atrophy
4. Wayne State University awarded $3 million from NIH to foster science and research careers
5. Wayne State researcher receives NSF award to develop neural implants
6. Wayne State University engineering student receives American Tinnitus Association award
7. Wayne State University researcher argues that sex reduces genetic variation
8. Health providers should emphasize breast cancer screening, Wayne State University research finds
9. Religion benefits traumatic brain injury victims, Wayne State University research finds
10. Wayne State University researchers win grant from the NSF to target tinnitus
11. Wayne State researchers find new way to examine major depressive disorder in children
Post Your Comments:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: